PTC Therapeutics (PTCT) PT Cut To $40 At Barclays After Sizable Translarna Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
PTC Therapeutics (PTCT) PT Lowered to $46 at RBC Capital
November 6, 2018 6:46 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $51.00) while maintaining an Outperform rating.
"3Q optics were unfavorable, given the Translarna miss, Emflaza guidance adjustment, and increased spend, and we could see shares trade off modestly," Abrahams commented.
... More